ipl-logo

Rcop And Chop Case Studies

929 Words4 Pages

outcomes of regimens involving R-CHOP and CHOP. Incremental cost per life year saved and per year of quality adjusted life year saved was reported as outcomes from the US societal perspective. The costs as well as survival rate was discounted at 3% fixed annual rate (Hornberger, J. C., & Best, J. H. (2005). Clinical outcomes in this study resulted in 53% patients with event-free survival at 3 years in R-CHOP and 35% in CHOP. It is estimated that R-CHOP would increase the mean event-free survival from 2.19 years with CHOP to 3.10 years (additional 0.90 years) and overall survival with R-CHOP would increase from 3.11 years with CHOP to 4.15 years (additional 1.04 years). The mean cumulative cost of R-CHOP was $17,225 and that of CHOP was $3358, …show more content…

The study was conducted by developing a Markov model which included three health states (unprogressed, progressed and death). The results were concluded over a time horizon of 15 years. In the base case analysis, three treatments were compared that included three courses of first line treatment (Rituximab to fludarabine and cyclophosphamide) which was followed by three courses of post-progression salvage treatment with three courses of fludarabine and cyclophosphamide followed by three courses of salvage treatment excluding rituximab. The model also predicted that the patients received an average of two courses of treatments (Adena, M., Houltram, J., Mulligan, S. P., Todd, C., & Malanos, G. …show more content…

Patients treated with rituximab were observed to have increased survival as well as quality adjusted survival resulting in high value of utility and also low death rate. Treatment with rituximab furthermore delays the time period until patients require successive chronic lymphocytic leukemia. For patients with progressed and unprogressed states, utility scores were 0.805 and 0.618 respectively which was obtained by EQ-5D questionnaire. The incremental cost per quality of life gained associated with R-FC in patients who were previously untreated was found out to be A$36,131 which was lower than in relapsed/refractory patients (A$41,645). The use of rituximab in untreated patients was found to be more cost effective when compared to relapse/refractory patients. With the addition of rituximab, the incremental cost is A$40,268 and the cost per quality adjusted life year gained was found out to be A$42,906. There was also an incremental gain of 0.94 quality adjusted life years with the addition of rituximab. The model used various regimens throughout its study and concluded that rituximab is cost-effective in combination with chemotherapy for the treatment of chronic lymphocytic leukemia (Adena, M., Houltram, J., Mulligan, S. P., Todd, C., & Malanos, G.

Show More
Related
418 Words | 2 Pages

During the interval two patients were censored (2+ and 3+) so that at the end of the interval four patients were still at risk. Since the interval ends with the death of one of those, the chance of surviving the interval is estimated as 3/4. Also notice that at the start of the next interval (4 through 10 years), only three patients were at risk due to the death at the end of the interval. The actual curve plotted from this computation is shown in Fig. 2.3.

Read More
300 Words | 2 Pages

Question 1 Patient : Samantha Gelly (F) D.O.B : 14/11/1993 Date : 08/09/2017 Samantha is a 23-year-old young woman. She had an injury on her right-sided head. During her soccer practice, she got hit in the right-sided head by a soccer ball. She stopped the practice after the injury and was conscious at the time.

Read More
1415 Words | 6 Pages

Vascular Failure Protocol By Dr. Radu Scurtu - Full Review Hi there and welcome to our review of the “Vascular Failure Protocol - The Simple, Easy Plan for Resetting Your Cardiovascular Health” by Dr. Radu Scurtu. Like always, this review will be divided into three main sections: 1. The basics section that covers the main things Dr. Radu Scurtu offers in his guide. 2. The pros and cons section that includes the most important pros and cons that we feel you need to know on Dr. Scurtu's Vascular Failure Protocol.

Read More
1263 Words | 6 Pages

Evidence Based Practice Proposal- Section D: Solution Description The Edmonson Psychiatric Fall Risk Assessment Tool (EPFRAT) to have higher sensitivity in assessing fall risk in the geri-psychiatric population (Edmonson et. al, 2011). This project of EPFRAT will let the progress of a fall risk prevention protocol to provide the safest environment and best quality of care possible for the geriatric psychiatric inpatient.

Read More
1118 Words | 5 Pages

Najla Morshidi NURS 301 Case Study Health History and Analysis of Finding A 75 year old female patient alert and oriented X 3, weigh 115 Lbs, her height 5?8?? , has a hearing aid and wear glasses for reading. The presented Patient has a history of hypertension diagnosed with CHF on 2013, positive for Hepatitis B due to contaminated blood transfusion. Had a cervical dysplasia on 1994 resolved by a total abdominal hysterectomy and bilateral oophorectomy the following year.

Read More
1193 Words | 5 Pages

Certainly, it is cheaper to give one dose of pills that end a suffering patient’s life than to keep them alive with whatever means physicians must use. As a matter of fact, William E Barlow, PhD (2009) claims that medical care for cancer alone is estimated to have cost the United States 89 billion dollars in 2007 (p. S33). This number would not be so high if we allowed people to have terminal cancer to put an end to their suffering. Again, this only takes cancer into consideration; there are numerous other terminal diseases that lead to nothing but suffering during the last few months of one’s life.

Read More
955 Words | 4 Pages

The point in his article is that different treatments cost different amounts, sometimes very significantly different, yet both get the same result. By doing comparative effectiveness research, patients can get the quality care they deserve but at a much cheaper cost. (Health care reform debate in the United States,

Read More
1252 Words | 6 Pages

The Horde Quarterly Report: As the FFB year starts, the Horde Institute understands that there is a demand for reliable investment information. Using hearsay, conjecture, rumors, and wild speculation, the H.I. seeks to illuminate the darkness and bring clarity to the FFB market. Assuredly no crystal ball exists, but with research and patients patterns can be revealed. This year, the H.I. will group the managers and their teams into three distinct categories.

Read More
529 Words | 3 Pages

Years of potential life lost is a calculation of the “weighted total of the number of deaths by age, with the weight for each age determined by the particular method of valuing potential remaining years of life (Gardner, J. and Sanborn, J).” In addition, years of potential life lost is used to “emphasize deaths at younger ages (Gardner, J. and Sanborn, J).” According to Changing the U.S. Health Care System, “the two largest contributors to the disproportionately high YPLL rate among African Americans are cancer and heart disease (2014).” Cancer is the most important contributor to YPLL because it is the “second leading cause of death but accounts for the largest YPLL per 100,000 for both males and females (Healthy People

Read More
1183 Words | 5 Pages

As an example, consider the treatment of patients with endocarditis caused by Staphylococcus aureus (SA). Although the mortality rate for this disease ranges from 25% to 47% , let us assume that in the population of interest, White males aged 30 to 60 the mortality rate is 38% with the standard antibiotic treatment of penicillin, methicillin, vancomycin and other antibiotics. However, a new drug has been developed that attacks the bacteria’s ability to protect itself from the human immune system rather than interfering with cell wall development. The question is this: What are the odds of dying with the new drug as opposed to the standard antibiotic therapy protocol? The odds ratio is a way of comparing whether the odds of a certain outcome is the same for two different groups.

Read More
1114 Words | 5 Pages

In the 1940s, one in 16 developed cancer. • In the 1970s, it was one in 10. • Today, it is one in three!

Read More
43 Words | 1 Pages

This assignment has impacted my perspective on evidence-based practice by helping me build clinical reasoning skills and knowledge of difference diagnoses that will enables me to apply the most high-quality and appropriate intervention strategies that is proven effective in improve patient’s treatment outcome.

Read More
5486 Words | 22 Pages

The objective is to critically evaluate the published literature relevant to cost-effectiveness analysis of interventions to prevent complications and

Read More
1170 Words | 5 Pages

the Figure 1.a Illustrates entry of patients during the period of the study the symbol ((▌ refers to that, the letter (D) indicates the occurrence of the event (i.e death), while the symbols (L) refers to the last follow-up, and (A) indicates that the patient is still alive after the end of the study. As for figure 1.b, the data are displayed in the form of survival analysis where death is the event of interest ,the letter (D) indicates the occurrence of the event like the patients 2, 6 and 7, and the patients who did not die and the last follow-up, are considered right-censored (C) such as 1,3,4 and

Read More
818 Words | 4 Pages

Delaying it may cause the cancer to reach the last stage which is where nothing can be done to cure it because the cancer has spread all over the body which will cause someone’s death. For me what I will do to prevent such a thing to happen to me or my closed love ones is whenever there are symptoms showing up I should not ignore it and instead I should immediately visit the doctor to avoid any further complications. I will also spread this to my closed love ones so that they will also be aware of how important it is to seek medical treatment early rather than delaying

Read More

More about Rcop And Chop Case Studies

Related Topics

Open Document